MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Salarius Pharmaceuticals Net Income 2011-2026 | SLRX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Salarius Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.5 M | -5.58 M | -12.5 M | -31.6 M | -12.8 M | -7.35 M | -6.94 M | -21.9 M | -34.4 M | -39.5 M | -29.1 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.58 M | -39.5 M | -19.5 M |
Quarterly Net Income Salarius Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -873 K | -958 K | -1.71 M | - | -972 K | -1.42 M | -1.72 M | - | -2.44 M | -3.88 M | -5.34 M | - | -14.4 M | -4.72 M | -6.11 M | - | -3.74 M | -3.07 M | -1.85 M | - | -1.72 M | -1.78 M | -2.08 M | - | -2.63 M | -904 K | -1.52 M | -2.01 M | -307 K | 111 K | -382 K | -8.03 M | -9.33 M | -8.8 M | -8.27 M | -7.9 M | -10.6 M | -11.4 M | -9.59 M | -7.89 M | -8.15 M | -7.08 M | -6.02 M | -3.74 M | -1.99 M | -2.19 M | -92.7 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 111 K | -14.4 M | -4.33 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptorum Group Limited
APM
|
-1.36 M | $ 0.87 | -0.11 % | $ 6.4 M |  China |
 |
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.18 | 1.95 % | $ 447 M |  USA |
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-847 M | $ 9.76 | 1.77 % | $ 631 M | USA |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 96.92 | -6.31 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | China |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 5.12 | 3.96 % | $ 799 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
226 M | $ 21.99 | -2.05 % | $ 3.64 B | USA |
 |
Cerus Corporation
CERS
|
-15.6 M | $ 2.89 | 42.45 % | $ 551 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-106 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
115 M | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-105 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-132 M | - | - | $ 3.74 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
-20 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-10.3 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-195 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-52.8 M | $ 1.44 | - | $ 235 M | France |
 |
Dynavax Technologies Corporation
DVAX
|
27.3 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-186 M | - | - | $ 28.6 M | USA |
 |
Editas Medicine
EDIT
|
-160 M | $ 2.88 | -4.17 % | $ 256 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.83 M | $ 2.97 | -6.9 % | $ 4.89 M | Israel |
 |
Edesa Biotech
EDSA
|
-6.17 M | $ 18.1 | -0.96 % | $ 57.9 M | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
-75 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-36.1 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
-120 M | - | - | $ 8.42 M | USA |
 |
Evogene Ltd.
EVGN
|
-30.4 M | $ 0.8 | 2.56 % | $ 27.9 M | Israel |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |